Entera Bio receives US FDA approval of IND application for EB613 – an oral human parathyroid hormone (1-34) for the treatment of osteoporosis ... Dec 11
This collaboration will help Crescendo’s proprietary transgenic platform and engineering expertise are being used to build Humabody-based therapeutics against certain targets selected by ... Dec 11
UX701 is currently in late preclinical development, and an investigational new drug (IND) application is expected to be filed with the US FDA by the ... Dec 11
WHO applauds India's initiative on promoting physical activity through this fitness campaign... Dec 11
It can be used to build constructs and minimize the time and cost of screening for perfect clones... Dec 11
The BMJ’s attempts to discover more have been thwarted ... Dec 11
-Advertisements-